Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Tools & Technology › Gene Silencing/Gene Editing › CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant

CRISPR Framework Helps Identify Combination Therapies for Optimal Targeting of KRAS Mutant

May 29, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Researchers from the University of California, San Francisco used a genome-scale CRISPR interference (CRISPRi) functional genomics platform to systematically identify genetic interactions with a mutant form of KRAS called KRASG12C, and found combination therapies that target genes involved in its activity.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Jul
16
Featured Webinar

Exploring Tumor Tissue Architecture and Immune Response with Digital Spatial Profiling

Join this webinar to learn how spatial resolution of gene expression in tumor tissue reveals new insights in biomarker discovery and therapeutic response. 

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In Cancer

  1. Precision Oncology Trials Still Enroll Mostly White Patients Despite Initiatives, Calls to Diversify

    Premium

  2. Menarini to Launch Trial Evaluating PI3K Inhibitor MEN1611 in Metastatic Colorectal Cancer

  3. Cancer AI Startup Nucleai Raises $6.5M in Series A Financing

  4. EMA Accepts Daiichi Sankyo's Application for Enhertu in HER2-Positive Breast Cancer

  5. Turning Point Therapeutics, Zai Lab Enter License Agreement for Repotrectinib in Greater China

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.